Telomir Pharmaceuticals, Inc. Payments of Financing Costs
Telomir Pharmaceuticals, Inc. (TELO) reported Payments of Financing Costs of $255.97 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow
us-gaap:PaymentsOfFinancingCosts · last filed 2024-03-29
- Telomir Pharmaceuticals, Inc. payments of financing costs for fiscal 2023 was $255.97K, a 441.04% increase from fiscal 2022.
- Telomir Pharmaceuticals, Inc. payments of financing costs for fiscal 2022 was $47.31K.
| Period end | Payments of Financing Costs 12 month |
|---|---|
| 2023-12-31 | $255.97K 10-K · filed 2024-03-29 |
| 2022-12-31 | $47.31K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |